ACAD
Price
$15.37
Change
-$0.75 (-4.65%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
2.69B
38 days until earnings call
RCKT
Price
$5.11
Change
-$0.45 (-8.09%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
591.79M
37 days until earnings call
Ad is loading...

ACAD vs RCKT

Header iconACAD vs RCKT Comparison
Open Charts ACAD vs RCKTBanner chart's image
ACADIA Pharmaceuticals
Price$15.37
Change-$0.75 (-4.65%)
Volume$30.42K
Capitalization2.69B
Rocket Pharmaceuticals
Price$5.11
Change-$0.45 (-8.09%)
Volume$62.22K
Capitalization591.79M
ACAD vs RCKT Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. RCKT commentary
Apr 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and RCKT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 05, 2025
Stock price -- (ACAD: $16.12 vs. RCKT: $5.56)
Brand notoriety: ACAD and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 90% vs. RCKT: 245%
Market capitalization -- ACAD: $2.69B vs. RCKT: $591.79M
ACAD [@Biotechnology] is valued at $2.69B. RCKT’s [@Biotechnology] market capitalization is $591.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileRCKT’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • RCKT’s FA Score: 1 green, 4 red.
According to our system of comparison, ACAD is a better buy in the long-term than RCKT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while RCKT’s TA Score has 4 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 6 bearish.
  • RCKT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RCKT is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -6.22% price change this week, while RCKT (@Biotechnology) price change was -29.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.75%. For the same industry, the average monthly price growth was -16.58%, and the average quarterly price growth was -18.37%.

Reported Earning Dates

ACAD is expected to report earnings on May 13, 2025.

RCKT is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-10.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.69B) has a higher market cap than RCKT($592M). ACAD YTD gains are higher at: -12.153 vs. RCKT (-55.768). ACAD has higher annual earnings (EBITDA): 100M vs. RCKT (-247.48M). ACAD has more cash in the bank: 756M vs. RCKT (372M). RCKT has less debt than ACAD: RCKT (25.5M) vs ACAD (52M). ACAD has higher revenues than RCKT: ACAD (958M) vs RCKT (0).
ACADRCKTACAD / RCKT
Capitalization2.69B592M454%
EBITDA100M-247.48M-40%
Gain YTD-12.153-55.76822%
P/E Ratio11.85N/A-
Revenue958M0-
Total Cash756M372M203%
Total Debt52M25.5M204%
FUNDAMENTALS RATINGS
ACAD vs RCKT: Fundamental Ratings
ACAD
RCKT
OUTLOOK RATING
1..100
604
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2597
PRICE GROWTH RATING
1..100
6295
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (28) in the Biotechnology industry is somewhat better than the same rating for ACAD (62). This means that RCKT’s stock grew somewhat faster than ACAD’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACAD (100). This means that RCKT’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (25) in the Biotechnology industry is significantly better than the same rating for RCKT (97). This means that ACAD’s stock grew significantly faster than RCKT’s over the last 12 months.

ACAD's Price Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for RCKT (95). This means that ACAD’s stock grew somewhat faster than RCKT’s over the last 12 months.

ACAD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RCKT (100). This means that ACAD’s stock grew similarly to RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADRCKT
RSI
ODDS (%)
Bullish Trend 5 days ago
74%
Bullish Trend 5 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 5 days ago
89%
Momentum
ODDS (%)
Bearish Trend 5 days ago
65%
Bearish Trend 5 days ago
84%
MACD
ODDS (%)
Bearish Trend 5 days ago
63%
Bearish Trend 5 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 5 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
76%
Bearish Trend 5 days ago
85%
Advances
ODDS (%)
Bullish Trend 18 days ago
74%
Bullish Trend 13 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
71%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
71%
Bullish Trend 5 days ago
73%
Aroon
ODDS (%)
Bearish Trend 5 days ago
77%
Bearish Trend 5 days ago
84%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X83102.830000617.109400
+0.75%
Bitcoin cryptocurrency
SPY536.70-27.82
-4.93%
SPDR® S&P 500® ETF Trust
TSLA267.28-15.48
-5.47%
Tesla
GME21.10-1.59
-7.01%
GameStop Corp
AAPL203.19-20.70
-9.25%
Apple

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with RGNX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-3.01%
RGNX - ACAD
45%
Loosely correlated
-5.39%
HRTX - ACAD
42%
Loosely correlated
-4.04%
STTK - ACAD
40%
Loosely correlated
-17.34%
XNCR - ACAD
39%
Loosely correlated
-9.16%
RCKT - ACAD
39%
Loosely correlated
-11.75%
More

RCKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with NTLA. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCKT
1D Price
Change %
RCKT100%
-11.75%
NTLA - RCKT
56%
Loosely correlated
-5.62%
RGNX - RCKT
54%
Loosely correlated
-5.39%
CRSP - RCKT
52%
Loosely correlated
-4.47%
ETNB - RCKT
51%
Loosely correlated
-4.59%
FATE - RCKT
50%
Loosely correlated
-11.69%
More